Alcon Acquires Majority Interest in Aurion Biotech, Inc.

Alcon Acquires Aerie Pharmaceuticals

August 22, 2022

Pharmaceuticals

Swiss eye-care leader Alcon has acquired Aerie Pharmaceuticals, a Durham, North Carolina-based ophthalmic pharmaceutical company, adding commercial products Rocklatan and Rhopressa as well as a clinical-stage pipeline including AR-15512. The acquisition strengthens Alcon's ophthalmic pharmaceutical capabilities and R&D expertise and is intended to expand distribution and accelerate development of Aerie's portfolio.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Alcon Acquires Ivantis, Inc.

January 10, 2022

Medical Devices

Alcon has completed its acquisition of Ivantis, Inc., the developer of the Hydrus Microstent, integrating Ivantis’ manufacturing and sales employees to expand Alcon’s global surgical ophthalmology portfolio. Alcon said it will leverage its global footprint to broaden Hydrus Microstent availability and continue clinical research, including pursuing stand‑alone surgery indications in the U.S.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

ABIONYX Pharma Acquires IRIS Pharma via Contribution in Kind

December 6, 2021

Biotechnology

ABIONYX Pharma completed a contribution in kind of 100% of the capital of IRIS Pharma Holding, issuing new ABIONYX shares at €3.60 per share to acquire the business. IRIS Pharma will become a subsidiary of ABIONYX while remaining operationally independent as a specialist CRO in ophthalmology, providing ABIONYX with ophthalmology R&D capabilities and a potential portfolio of biologic candidates.